Technical Analyst Radhika Gupta of Forefront Capital Management has maintained 'buy' rating on Lupin Ltd stock.

According to analyst, the investors can buy the stock to reap good returns in the long run.

Today, the stock of the company opened at Rs 1860 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1881 and a low of Rs 754.90 on BSE.

Current EPS & P/E ratio stood 76.61 and 23.91 respectively.

Indian drug maker Lupin Ltd is all set to sign up its second deal in Japan, where it turned the seventh biggest generics player after getting hold of Kyowa Pharmaceuticals Ltd in the year 2007 for Rs 46.5 crore.

Lupin's executive director Nilesh Gupta said that the target company engages in the generic injectable drugs sector, and will projected to be valued in the same range as Kyowa.

Moreover, Lupin will establish a research and development (R&D) facility to exclusively manufacture generic drugs for the growing market segments in Latin America, Africa and Australia.

Lupin said that it will hire around 50-60 people for its new facility.

The r&d plant is expected to be ready in Aurangabad within the next 3 months.

Nilesh Gupta, group president and executive director said that the company presently has an R&D team of 700-plus scientists.